Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria

现有的HT CBB试剂盒能够高通量提取专为HiFi量身定制的HMW DNA，并具有针对动物血液和细菌的更新工作流程

MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects..

加利福尼亚州门洛帕克，2024年1月15日/PRNewswire/-PacBio（纳斯达克股票代码：PACB）是高质量、高精度测序解决方案的领先开发商，今天宣布了PanDNA，一种多功能的纳米结合DNA提取试剂盒。这一新产品扩展了适用于长读测序的样本类型，包括细胞、细菌、血液、组织、植物细胞核和昆虫。。

Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types. These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings. Their simple, rapid protocol is compatible with platforms from PacBio's Compatible automation providers..

Nanobind试剂盒专为研究人员设计，可在多种样品类型中有效提取高质量，高分子量的DNA。这些试剂盒是多功能的，既可以手动（Nanobind PanDNA试剂盒）也可以高通量（Nanobind CBB HT试剂盒）设置。他们简单、快速的协议与PacBio兼容自动化提供商的平台兼容。。

In addition, based on customer feedback, the existing high-throughput extraction Nanobind HT CBB kit will now support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run.

此外，根据客户反馈，现有的高通量提取Nanobind HT CBB试剂盒现在将支持两种新的样品类型-动物血液和细菌-每次运行可容纳96个样品。

'The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing,' said Jeff Eidel, Chief Commercial Officer at PacBio. 'We continue to enable our customers with products such as the PanDNA kit that support researchers to complete accurate genome assemblies, identify structural variants, and explore complex biological systems in extraordinary detail using our Revio sequencing system.'.

PacBio首席商务官杰夫·艾德尔（JeffEidel）说，新的PanDNA试剂盒将成为提取针对高保真测序优化的DNA的通用试剂盒我们继续为客户提供PanDNA试剂盒等产品，支持研究人员使用我们的Revio测序系统完成准确的基因组组装，识别结构变异，并非常详细地探索复杂的生物系统。”。

'Nanobind high molecular weight DNA extraction is a game-changer for us and having one universal kit for all supported samples is very convenient,' said Igor Stevanovski, Research Assistant at the Genomic Technologies Lab, Garvan Institute of Medical Research – one of Australia's premier medical research institutes.

澳大利亚首屈一指的医学研究机构加万医学研究所基因组技术实验室的研究助理伊戈尔·斯特瓦诺夫斯基（IgorStevanovski）说：“Nanobind高分子量DNA提取对我们来说是一个游戏规则的改变者，拥有一个用于所有支持样本的通用试剂盒非常方便。”。

'The flexibility offered by the PanDNA kit will support our broad research community to answer those key questions and make important biological discoveries.'.

“PanDNA试剂盒提供的灵活性将支持我们广泛的研究社区回答这些关键问题并做出重要的生物学发现。”。

'The Darwin Tree of Life project aims to generate high quality genomes for 70,000 species of plants, fungi, animals and protists across Britain and Ireland. High-throughput solutions such as the Nanobind CBB HT kit are critical for efforts like these,' said Caroline Howard, Senior Scientific Manager, Tree of Life Programme at the Wellcome Sanger Institute.

“达尔文生命树项目旨在为英国和爱尔兰的70000种植物、真菌、动物和原生生物生成高质量的基因组。惠康桑格研究所生命之树项目高级科学经理卡罗琳·霍华德（CarolineHoward）说，诸如Nanobind CBB HT试剂盒等高通量解决方案对于此类工作至关重要。

'The Nanobind kits combined with the Revio system address these needs by significantly increasing throughput. Using the kits, we were able to generate 30x coverage of HiFi data sufficient for de novo assembly.'.

“Nanobind试剂盒与Revio系统相结合，通过显着提高吞吐量来满足这些需求。使用这些套件，我们能够产生30倍的HiFi数据覆盖率，足以进行从头组装。”。

The new PanDNA kit is expected to be available for purchase and shipment in February 2024. The Nanobind HT CBB kit is available now. For more information, visit the Nanobind extraction kit page here.

新的PanDNA套件预计将于2024年2月购买和装运。Nanobind HT CBB试剂盒现已上市。有关更多信息，请访问此处的Nanobind提取工具包页面。

About PacBioPacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies.

关于PacBioPacBio（纳斯达克股票代码：PACB）是一家领先的生命科学技术公司，正在设计、开发和制造先进的测序解决方案，以帮助科学家和临床研究人员解决遗传复杂问题。我们的产品和技术源自两项高度分化的核心技术，专注于准确性、质量和完整性，其中包括我们的HiFi长读测序和SBB®短读测序技术。

Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio..

我们的产品解决了广泛的研究应用问题，包括人类种系测序、植物和动物科学、传染病和微生物学、肿瘤学以及其他新兴应用。有关更多信息，请访问www.pacb.com并关注@PacBio。。

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

PacBio产品仅供研究使用。不用于诊断程序。

Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to future availability, uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including Nanobind PanDNA kits; statements regarding DNA extraction across a wide range of sample types; PanDNA kits as a go-to kit for HiFi sequencing and its ability to support a broad research community; among other future events.

前瞻性声明本新闻稿可能包含经修订的《1934年证券交易法》第21E节和《1995年美国私人证券诉讼改革法》所指的“前瞻性声明”。除历史事实陈述外的所有陈述均为前瞻性陈述，包括与PacBio产品或技术（包括Nanobind PanDNA试剂盒）的未来可用性、用途、优势、质量或性能或使用的益处或预期益处有关的陈述；关于多种样品类型的DNA提取的声明；PanDNA试剂盒作为HiFi测序的go-to试剂盒及其支持广泛研究社区的能力；以及其他未来的事件。

Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements.

提醒读者不要过度依赖这些前瞻性陈述，任何此类前瞻性陈述均参考以下警示性陈述进行整体限定。所有前瞻性声明仅在本新闻稿发布之日发表，均基于当前预期，并涉及一些可能导致实际结果与此类前瞻性声明存在重大差异的假设、风险和不确定性。

These risks include, but are not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products; potential product performance and quality issues and potential delays in development and commercialization timelines; rapidly changing technologies and extensive competition in genomic sequencing that could make the products PacBio is developing obsolete or non-competitive; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights.

这些风险包括但不限于开发、制造、发布、营销和销售新产品所固有的挑战；潜在的产品性能和质量问题以及开发和商业化时间表的潜在延迟；快速变化的技术和基因组测序的广泛竞争可能使PacBio的产品变得过时或不具竞争力；以及第三方声称侵犯专利和专有权利或试图使PacBio的专利或专有权利无效的索赔。

Readers are strongly en.

读者们都很兴奋。

Contacts

联系人

Investors:Todd Friedman[email protected]

投资者：托德·弗里德曼[受电子邮件保护]

Media:Lizelda Lopez[email protected]

媒体：Lizelda Lopez[受电子邮件保护]

SOURCE Pacific Biosciences of California, Inc.

来源：加利福尼亚太平洋生物科学公司。